It looks like your browser does not have JavaScript enabled. Please turn on JavaScript and try again.
Advanced Search
Toggle navigation
Commercial
Home
Commercial Policies
Currently selected
Medicare Advantage Policies
MA PPO Host Policies
Contact Us
Commercial
Medical Policy
Policy Bulletins
Currently selected
Active Policy Notifications
Policy Types and Descriptions
Services Requiring Precertification
Coverage Guidelines
Select Cardiology Guidelines
Diagnostic Radiology Guidelines
Lab Management Guidelines
Musculoskeletal Guidelines
Radiation Therapy Guidelines
Sleep Disorder Management Guidelines
Specialty Medical Benefit Drugs
News & Announcements
Site Activity
Contact Us
Published
Notification
Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects
Notification Issue Date:
MPNotificationDescriptionPub
Title:
Contact Lenses for the Treatment of Persistent (Corneal) Epithelial Defects
Policy #:
07.13.11k
MPNewsFLASHPub
Policy
MPPolicyPub
The use of either rigid gas-permeable scleral contact lenses (e.g., BOSTON® Scleral Lens,
now known as the
BostonSight
®
PROSE device
) or therapeutic soft contact lenses
(e.g., Focus® Night & Day® Lens) as corneal liquid bandages is considered medically necessary and, therefore, covered for individuals who meet both of the following criteria:
The individual has persistent epithelial defects (PEDs) of the cornea with documented, disabling symptoms (e.g., pain, photophobia) that have not responded to medical intervention.
The individual has any of the following conditions for which surgery is undesirable and/or contraindicated:
Stevens-Johnson disease
(a syndrome of systemic, as well as more severe, mucocutaneous lesions that results in corneal opacities, perforations, and/or blindness)
Conditions that result from a chemical and/or traumatic injury
Postradiotherapy complications
Recurrent corneal erosion
Congenital and/or postsurgical eyelid defect(s)
Ocular cicatricial pemphigoid
Exposure keratitis
Toxic epidermal necrolysis
Lacrimal and/or meibomian gland obliteration or deficiency
Superior limbal keratoconjunctivitis
Sjögren syndrome
Inflammatory corneal degeneration
Neurotrophic corneal disease (e.g., corneal denervation that is
related to acoustic neuroma surgery,
trigeminal ganglion obliteration, diabetes mellitus, herpetic syndrome, congenital dysautonomia [e.g., Riley-Day syndrome])
PED resulting from superior limbic keratotomy
Corneal ectatic disorders (e.g., keratoconus, keratoglobus, pellucid marginal degeneration, Terrien’s marginal degeneration, Fuchs’ superficial marginal keratitis, post-surgical ectasia)
Chronic ocular graft-versus-host disease (GVHD)
Irregular corneal astigmatism (e.g., after keratoplasty, photorefractive keratectomy, other corneal surgery)
Post-ocular surface tumor excision
The use of therapeutic soft contact lenses as corneal liquid bandages is considered medically necessary and, therefore, covered for individuals who meet both of the following criteria:
The individual has a PED with documented, disabling symptoms (e.g., pain, photophobia) that have not responded to medical intervention.
The PED is associated with any of the following conditions:
Bullous keratopathy
Permanent keratoprosthesis
Filamentary keratitis
PEDs resulting from penetrating keratoplasty
Following the use of cyanoacrylate (tissue) glue to provide protection to this adhesive plug over a corneal wound
REQUIRED DOCUMENTATION
The individual's medical record must reflect the medical necessity for the care provided. These medical records may include, but are not limited to: records from the health care professional's office, hospital, nursing home, home health agencies, therapies, and test reports.
The Company may conduct reviews and audits of services to our members, regardless of the participation status of the provider. All documentation is to be available to the Company upon request. Failure to produce the requested information may result in a denial for the service.
Guidelines
MPGuidelinesPub
BENEFIT APPLICATION
Subject to the terms and conditions of the applicable benefit contract, corneal liquid bandages are covered under the medical benefits of the Company’s products when the medical necessity criteria listed in this medical policy are met.
THE BOSTON® SCLERAL LENS (BSL) -- (NOW KNOWN AS BOSTONSIGHT® PROSE DEVICE)
The BOSTON® Scleral Lens (BSL) and all care associated with its fitting are only available at the Boston Foundation for Sight (Needham Heights, MA).
Other lenses (including rigid gas-permeable lenses and therapeutic soft
lenses) may be available through Company-contracted providers.
US FOOD AND DRUG ADMINISTRATION (FDA) STATUS
The BSL was approved by the FDA on March 1, 1994.
Supplemental approvals for rigid gas-permeable scleral and soft therapeutic contact lenses have since been issued by the FDA.
BSL is now known as the
BOSTONSIGHT® PROSE DEVICE.
Description
MPDescriptionPub
The term corneal liquid bandage applies to both rigid gas-permeable scleral contact lenses (RGP-ScCLs) and therapeutic soft contact lenses (TSCLs). Corneal liquid bandages cover the cornea and sometimes the adjacent portion of the white of the eye (sclera) and are used in the treatment of acute or chronic corneal pathology such as persistent epithelial defects (PEDs). PEDs are defined as lesions or serious deformities
of the cornea that persist despite the use of conventional therapies. PEDs are associated with certain systemic or eye diseases and/or may develop following penetrating keratoplasty (PK).
Corneal liquid bandages protect the corneal surface from the drying effects of exposure to air and the friction of blinking. They also significantly reduce the intensity of ocular pain and photophobia associated with ocular surface disease and facilitate the healing of PEDs. Corneal liquid bandages can also eliminate superficial corneal irregularities and thus may improve visual acuity during treatment.
The objectives of corneal liquid bandages are summarized as:
Relief of ocular pain
Promotion of corneal healing
Mechanical protection and support
Maintenance of corneal epithelial hydration
Installation of medications
Corneal liquid bandages are utilized in a large variety of ophthalmic disorders and are considered one of various treatment options. The choice of lens depends on the clinical effect best suited to the corneal condition, though typically TSCLs are tried first.
TYPES OF CORNEAL LIQUID BANDAGES
RIGID GAS-PERMEABLE SCLERAL CONTACT LENSES (RGP-ScCLs)
In the United States (US), scleral contact lenses were previously most often made of a rigid plastic. However, in recent years, a gas-permeable polymer plastic (e.g., fluorosilicone/acrylate polymer) has been used to make these lenses, which are now referred to as RGP-ScCLs. RGP-ScCLs
are promoted for daily use and, in some instances, extended use in the treatment of PEDs.
The BOSTON® Scleral Lens (BSL)
(
now known as the BostonSight
®
PROSE device
),
which is more specifically termed the BOSTON® Equalens® II, is a
RGP-ScCL commercially available in the US that can be post-fabricated
for the treatment of PEDs. Currently, it is manufactured
and distributed by the Boston Foundation for Sight (BFS) (Needham Heights, MA).
The BSL, unlike a traditional rigid gas-permeable contact lens, is a specially designed, fluid-ventilated, gas-permeable scleral c
o
ntact lens.
It is designed to maintain a bubble-free reservoir of oxygenated aqueous fluid over the corneal surface at a neutral hydrostatic pressure. Due to the fact that air bubbles are avoided, the fluid reservoir functions as a corneal liquid bandage that offers unique therapeutic benefits for the management of severe ocular surface disease, in addition to its traditional role of masking irregular corneal astigmatism.
In addition to BSL, additional sclera lens designs are also available (e.g., the Jupiter Mini-scleral gas-permeable contact lens). Although these come in various diameters, they are not custom fitted to each individual’s condition.
THERAPEUTIC SOFT CONTACT LENSES (TSCLs)
TSCLs are made of poly(2-hydroxyethyl methacrylate) or other polymer materials that are hydrophilic to absorb or attract a certain volume of water. These soft lenses are intended to be worn directly against the cornea and adjacent to the limbal and scleral areas of the eye to act as a corneal bandage in the treatment of acute or chronic corneal pathology such as PEDs. There are many types of soft lenses available for therapeutic use (e.g., Focus® Night & Day® Lens [CIBA Vision® Corporation, Duluth, GA; now Alcon Laboratories, Inc. Fort Worth, TX]). The cause of the PED should dictate which type of lens is used.
Indications
associated with PEDs, and for which corneal liquid bandages
(RGP-ScCLs and TSCLs) are sometimes recommended, include:
Stevens-Johnson disease (a syndrome of systemic, as well as more severe, mucocutaneous lesions that results in corneal opacities, perforations, and/or blindness)
Conditions that result from a chemical and/or traumatic injury
Postradiotherapy complications
Recurrent corneal erosion
Congenital and/or postsurgical eyelid defect(s)
Ocular cicatricial pemphigoid
Exposure keratitis
Toxic epidermal necrolysis
Congenital deficiency of the meibomian gland
Superior limbal keratoconjunctivitis
Sjögren syndrome
Inflammatory corneal degeneration
Neurotrophic corneal disease(s) (
e.g
.
, corneal denervation that is related to acoustic neuroma surgery, trigeminal ganglion obliteration, diabetes mellitus, herpetic syndrome, congenital dysautonomia [e.g., Riley-Day syndrome])
PEDs resulting from superior limbic keratotomy
Corneal ectatic disorders (e.g., keratoconus, keratoglobus, pellucid marginal degeneration, Terrien’s marginal degeneration, Fuchs’ superficial marginal keratitis, post-surgical ectasia
Chronic ocular graft-versus-host disease (GVHD)
Irregular corneal astigmatism (e.g., after keratoplasty, photorefractive keratectomy, other corneal surgery)
Post-ocular surface tumor excision
Additional indications where TSCLs are sometimes recommended include:
Bullous keratopathy
Permanent keratoprosthesis
Filamentary keratitis
PEDs resulting from penetrating keratoplasty
Following the use of cyanoacrylate (tissue) glue to provide protection to this adhesive plug over a corneal wound
References
MPReferencesPub
American Academy of Ophthalmology. EyeWiki™. BostonSight PROSE (Prosthetic replacement of the ocular surface ecosystem) and Scleral Contact Lenses. Last modified 05/27/2024. Available at:
http://eyewiki.aao.org/BostonSight_PROSE_(Prosthetic_replacement_of_the_ocular_surface_ecosystem)
. Accessed July 10, 2024.
American Academy of Ophthalmology. EyeWiki™. Corneal Epithelial Defect. Last modified 07/05/2024. Available at:
http://eyewiki.aao.org/Corneal_Epithelial_Defect
.
Accessed
July 10
,
2024
.
Baran I, Bradley JA, Alipour F, et al. PROSE treatment of corneal ectasia.
Cont Lens Anterior Eye.
2012;35(5):222-227.
Centers for Medicare & Medicaid Services (CMS).
National Coverage Determination (NCD).
80.1: Hydrophilic contact lens for corneal bandage. [CMS Web site]. ND. Available at:
http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=136&ncdver=1&bc=AAAAQAAAAAAA&
.
Accessed
July 10
,
2024
.
Centers for Medicare & Medicaid Services (CMS).
National Coverage Determination (NCD).
80.5: Scleral Shell. [CMS Web site]. ND. Available at:
http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=235&ncdver=1&bc=AgAAQAAAAAAA&
.
Accessed
July 10
,
2024
.
Ciralsky JB, Chapman KO, Rosenblatt MI, et al. Treatment of Refractory Persistent Corneal Epithelial Defects: A Standardized Approach Using Continuous Wear PROSE Therapy.
Ocul Immunol Inflamm.
2015;23(3):219-24.
Gungor I, Schor K, Rosenthal P, et al. The Boston Scleral Lens in the treatment of pediatric patients.
J AAPOS.
2008;12(3):263-267.
Jacobs DS, Rosenthal P. Boston sclera lens prosthetic device for treatment of severe dry eye in chronic graft-versus host disease.
Cornea.
2007; 26(10):1195-9.
Jupiter DG, Katz HR. Management of irregular astigmatism with rigid gas permeable contact lenses.
CLAO J.
2000; 26(1):14-7.
Kok JH, Visser R. Treatment of ocular surface disorders and dry eyes with high gas-permeable scleral lenses.
Cornea.
1992;11(6):518-522.
Pecego M, Barnett M, Mannis MJ, et al. Jupiter Scleral Lenses: the UC Davis Eye Center experience.
Eye Contact Lens.
2012; 38(3):179-82.
Puangsricharern V, Tseng SC. Cytologic evidence of corneal diseases with limbal stem cell deficiency.
Ophthalmology.
1995;102(10):1476-1485.
Pullum KW, Buckley RJ. A study of 530 patients referred for rigid gas permeable scleral contact lens assessment.
Cornea.
1997;16(6):612-622.
Romero-Rangel T, Stavrou P, Cotter J, et al. Gas-permeable scleral contact lens therapy in ocular surface disease.
Am J Ophthalmol.
2000;130(1):25-32.
Rosenthal P, Cotter J. The Boston Scleral Lens in the management of severe ocular surface disease.
Ophthalmol Clin North Am.
2003;16(1):89-93.
Rosenthal P, Cotter JM, Baum J. Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens.
Am J Ophthalmol.
2000;130(1):33-41.
Rosenthal P, Croteau A. Fluid-ventilated, gas-permeable scleral contact lens is an effective option for managing severe ocular surface disease and many corneal disorders that would otherwise require penetrating keratoplasty.
Eye Contact Lens.
2005;31 (3):130-134.
Rosenthal P, Jacobs DS, Johns L. Fluid-ventilated gas permeable scleral lens: a new paradigm for the management of irregular corneal astigmatism and severe ocular surface disease.
Contemporary Ophthalmology.
2006;5(22):1-7.
Segal O, Barkana Y, Hourovitz D, et al. Scleral contact lenses may help where other modalities fail.
Cornea.
2003;22(4):308-310.
Shipra Gupta S, Gupta P, Sayegh R. Healing a Persistent Corneal Epithelial Defect.
EyeNet Magazine.
August 2014. Available at:
https://www.aao.org/eyenet/article/healing-persistent-corneal-epithelial-defect
.
Accessed
July 10
,
2024
.
Schornack MM, Patel SV. Scleral lenses in the management of keratoconus.
Eye
Contact Lens.
2010; 36(1):39-44.
Schornack MM, Pyle J, Patel SV. Scleral lenses in the management of ocular surface disease.
Ophthalmology.
2014;121(7):1398-1405.
Smith GT, Mireskandari K, Pullum KW. Corneal swelling with overnight wear of scleral contact lenses.
Cornea.
2004;23(1):29-34.
Stason WB, Razavi M, Jacobs DS, et al. Clinical benefits of the Boston Ocular Surface Prosthesis.
Am J Ophthalmol.
2010; 149(1):54.61.
Tan DT, Pullum KW, Buckley RJ. Medical applications of scleral contact lenses: 2. Gas-permeable scleral contact lenses.
Cornea.
1995;14(2):130-137.
Tappin MJ, Pullum KW, Buckley RJ. Scleral contact lenses for overnight wear in the management of ocular surface disorders.
Eye (Lond).
2001;15(Pt 2):168-172.
Tseng SC, Tsubota K. Important concepts for treating ocular surface and tear disorders.
Am J Ophthalmol.
1997;124(6):825-835.
US Department of Health and Human Services, Health Care Financing Administration (HCFA). Hydrophilic contact lens for corneal bandage. Medicare Coverage Issues Manual §45-7. Baltimore, MD: HCFA; 1999. Revised 2010.
US Food and Drug Administration (FDA). Center for Devices and Radiological Health. BOSTON(R) EQUALENS (R) SCLERAL CONTACT LENS DESIGN. Premarket Approval (PMA) Database. [FDA Web site]. 03/01/1994. Available at:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P860022S040
.
Accessed
July 10
,
2024
.
US Food and Drug Administration (FDA). Center for Devices and Radiological Health. NIGHT & DAY 30 NIGHT EXTENDED WEAR SOFT CONTACT LENS. Premarket Approval (PMA) Database. [FDA Web site]. 03/19/2003. Available at:
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P010019S002
.
Accessed
July 10
,
2024
.
Visser ES, Visser R, van Lier HJ, et al. Modern scleral lenses part I: clinical features.
Eye Contact Lens.
2007;33(1):13-20.
Coding
CPT Procedure Code Number(s)
MPCPTCodesPub
N/A
ICD - 10 Procedure Code Number(s)
MPICD10ProcCodesNarrativesPub
N/A
ICD - 10 Diagnosis Code Number(s)
MPICD10DiagCodesNarrativesPub
See Attachment A.
HCPCS Level II Code Number(s)
MPHCPCSCodesNarrativesPub
S0515 Scleral lens, liquid bandage device, per lens
V2531 Contact lens, scleral, gas permeable, per lens (for contact lens modification, see 92325)
Revenue Code Number(s)
MPRevenueCodesNarrativesPub
N/A
MPMiscCodesNarrativesPub
MPCodeNarrativePub
Coding and Billing Requirements
MPCodingAndBillingPub
Cross Reference
{"8891":{"Id":8891,"MPAttachmentLetter":"A","Title":"ICD-10 Codes"}}
Policy History
Version Effective Date:
10/1/2021
Version Issued Date:
10/1/2021
Version Reissued Date:
7/24/2024
07.13.11
Medical Policy Bulletin
Commercial
MPattachmentdataPub
{"6534": {"Id":6534,"MPAttachmentLetter":"A","Title":"ICD-10 Codes","MPPolicyAttachmentInternalSourceId":8891,"PolicyAttachmentPageName":"008ec9e5-6f90-4469-8add-4589230fd5d3"},}
No
Decline
Accept and go to Medical Policies
|
Decline